Octreotide Inhibits the Secretion of Interleukin-12 from Mononuclear Cells in Human Peripheral Blood (PBMCs) In Vitro [1]

Introduction

The functional interactions between endocrine and immune systems play a relevant role in many basic physiological and pathological events such as cell proliferation and angiogenesis [1] [2]. Angiogenesis is a process of blood capillaries development during normal tissue proliferation (wound healing, embryogenesis) as well as during infection, ischemia, and cancer diseases. In vivo, several angiogenic modulators have been recognized in human and other species’ peptide molecules, such as vascular endothelial growth factor [2], interleukin-8 [3], and interleukin-12 [4]. Therefore, chemists have designed a lot of angiogenesis inhibitors, but only some of them are useful in clinical practice [5]. Octreotide (Sandostatin, SMS 201-995) is one of the somatostatin analogs and has been clinically useful in oncology, endocrinology and hematology for its strong inhibitory activity on multiple cell type proliferation and hormonal secretory processes [6]. Antiproliferative and antiangiogenic properties of somatostatin or octreotide are a result of binding with specific receptors. The five subtypes of somatostatin receptors have been discovered (SRRT 1-5) and described [6] [7]. The presence of somatostatin receptors on immune cells (monocytes and lymphocytes) indicates that octreotide (OCT) may be one of the regulators of the immune cell function in humans [3] [8]. However, there is no data in literature about the effect of OCT on interleukin-12 (IL-12) secretion from immune cells in human peripheral blood.

The aim of the study was to evaluate the influence of octreotide on IL-12 release from human peripheral blood mononuclear cells (PBMCs) in vitro.

1 This study was supported by a grant from Medical University of Łódź (502 - 11 - 488).

References

• 1 Woessner J F. Matrix metalloproteinase inhibition. From the Jurassic to the third millennium.  Ann New York Acad Sci. 1999;  878 388-403
• 2 Ławnicka H, Stępień H, Wyczółkowska J, Kolago B, Kunert-Radek J, Komorowski J. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture.  Biochem Biophys Res Comm. 2000;  268 567-571
• 3 Komorowski J, Jankiewicz-Wika J, Stępień H. Somatostatin (SOM) and octreotide (OCT) inhibit the secretion of interleukin-8 (IL-8) from human peripheral blood mononuclear cells (PBMC) in vitro. .  Horm Metab Res. 2000;  32 337-338
• 4 Voest E E, Kenyon B M, O’Reily M S, Truitt G, D’Amato R J, Folkman J. Inhibition of angiogenesis in vivo by interleukin-12.  J Natl Cancer Inst. 1995;  87 581-586
• 5 Woltering E A, Watson J C, Alperin-Lea C, Sharma C, Keenan E, Kurozawa D, Barrie R. Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action.  Invest New Drugs. 1997;  15 77-86
• 6 Lamberts S WJ. Octreotide: The next decade.  Bristol, UK:; BioScientifica Ltd, 1999
• 7 Tsutsumi A, Takano H, Ichikawa K, Kobayashi S, Kokike T. Expression of somatostatin receptor subtype 2 mRNA in human lymphoid cells.  Cell Immunol. 1997;  181 44-49
• 8 Komorowski J, Stępień H. Somatostatin (SRIF) stimulates the release of interleukin-6 (IL-6) from human peripheral blood monocytes (PBM) in vitro. .  Neuropeptides. 1995;  29 77-81
• 9 Storkus W J. Interleukin-12. In: Thomson AW (ed). The Cytokine Handbook. 3rd Edition.  San Diego:; Academic Press, 1998: 391-425
• 10 De Menis E, Tramontin P, Conte N. Danazol and multiple hepatic adenomas: peculiar clinical findings in an acromegalic patient.  Horm Metab Res. 1999;  8 476-477

1 This study was supported by a grant from Medical University of Łódź (502 - 11 - 488).